Sarah Hartmann
Harvard University
14 Papers
Sarah Hartmann is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque.
Zsofia D. Drobni,Zsofia D. Drobni,Raza M. Alvi,Jana Taron,Amna Zafar,Sean P. Murphy,Paula K. Rambarat,Rayma C. Mosarla,Charlotte E. Lee,Daniel A. Zlotoff,Vineet K. Raghu,Sarah Hartmann,Hannah K Gilman,Jingyi Gong,Leyre Zubiri,Ryan J. Sullivan,Kerry L. Reynolds,Thomas Mayrhofer,Lili Zhang,Udo Hoffmann,Tomas G. Neilan +20 more
TL;DR: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis and increased atherosclerotic plaque progression was attenuated with concomitant use of statins or corticosteroids.
379
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.
Paaladinesh Thavendiranathan,Lili Zhang,Amna Zafar,Zsofia D. Drobni,Syed S. Mahmood,Marcella Cabral,Magid Awadalla,Anju Nohria,Daniel A. Zlotoff,Franck Thuny,Lucie Heinzerling,Ana Barac,Ryan J. Sullivan,Carol L. Chen,Dipti Gupta,Michael C. Kirchberger,Sarah Hartmann,Jonathan W. Weinsaft,Hannah K Gilman,Muhammad A. Rizvi,Bojan Kovacina,Caroline Michel,Gagan Sahni,Ana González-Mansilla,Antonio Calles,Francisco Fernández-Avilés,Michael Mahmoudi,Kerry L. Reynolds,Sarju Ganatra,Juan José Gavira,Nahikari Salterain González,Manuel Garcia De Yebenes Castro,Raymond Y. Kwong,Michael Jerosch-Herold,Otavio R. Coelho-Filho,Jonathan Afilalo,Eduardo Zatarain-Nicolás,A. John Baksi,Bernd J. Wintersperger,Oscar Calvillo-Argüelles,Stéphane Ederhy,Eric H. Yang,Alexander R. Lyon,Michael G. Fradley,Tomas G. Neilan +44 more
TL;DR: The use of T1 mapping and application of the modified Lake Louise Criteria provides important diagnostic value, and T 1 mapping provides prognostic value in patients with ICI myocarditis.
139
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
Carlos Gongora,Zsofia D. Drobni,Thiago Quinaglia Araujo Costa Silva,Amna Zafar,Jingyi Gong,Daniel A. Zlotoff,Hannah K Gilman,Sarah Hartmann,Supraja Sama,Sofia Nikolaidou,Giselle A. Suero-Abreu,Eric N. Jacobsen,Jeremy S. Abramson,Ephraim P. Hochberg,Jeffrey A. Barnes,Philippe Armand,Paaladinesh Thavendiranathan,Anju Nohria,Tomas G. Neilan +18 more
TL;DR: In this article , a randomized clinical trial was conducted to test the cardiac efficacy and overall safety of SGLT2 inhibitors in patients treated with anthracyclines, and the results showed that SGLt2 inhibitors appeared to be safe.
78
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis.
Zsofia D. Drobni,Zsofia D. Drobni,Amna Zafar,Leyre Zubiri,Daniel A. Zlotoff,Raza M. Alvi,Charlotte E. Lee,Sarah Hartmann,Hannah K Gilman,Alexandra-Chloé Villani,Anju Nohria,John D. Groarke,Ryan J. Sullivan,Kerry L. Reynolds,Lili Zhang,Tomas G. Neilan +15 more
TL;DR: A reduction in ALC and an increase in NLR was seen with ICI myocarditis and a greater decrease or increase inNLR was associated with subsequent major adverse cardiac events.
51
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm.
Amna Zafar,Zsofia D. Drobni,Ramya C. Mosarla,Raza M. Alvi,Matthew Lei,Uvette Lou,Vineet K. Raghu,Sean P. Murphy,Maeve Jones-O'Connor,Sarah Hartmann,Hannah K Gilman,Colin D. Weekes,John W. Clark,Jeffrey W. Clark,Lawrence S. Blaszkowsky,Erica Tavares,Tomas G. Neilan +16 more
- 01 Mar 2021
TL;DR: In this paper, the authors conducted a retrospective analysis of all patients who received 5-fluorouracil (5-FU) at a single tertiary care center from January 2009 to July 2019.
46